ARMP
Armata Pharmaceuticals, Inc.
NYSE AmericanUSDEQUITY
Healthcare
DELAYED
Last price
5.10
▲ 0.68 (15.38%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
4.41
Prev close
4.42
Day high
5.10
Day low
4.46
Volume
105.50K
Market cap
$189.63M
P/E (TTM)
—
52W range
2.40 – 16.34
Day trading desk
Gap from prior close
-0.23%
Prior close 4.42
VWAP
4.80
+6.14% from price
Relative volume
0.72×
Normal
Session range
15.65%
4.41 – 5.10
Position in range
100%
Near session high
ATR (14D)
0.53
10.45% of price
Prior day high
5.17
PDH
Prior day low
4.12
PDL
Bid / ask spread
—
Quote not published
Session volume
109.36K
Avg 151.70K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+11.84%
+13.2%
1M
-2.30%
-6.0%
3M
-38.03%
-41.1%
6M
-41.58%
-52.6%
YTD
-18.79%
-31.1%
1Y
+103.19%
+83.2%
3Y
+27.18%
-47.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ARMP open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
25.15M
Total on file
Fundamentals
Market cap$189.63M
Enterprise value$479.63M
Revenue (TTM)$5.54M
Gross profit$-12.05M
EBITDA$-33.45M
Net income$-192.18M
EPS (TTM)$-5.29
Free cash flow$-27.41M
Total cash$23.95M
Total debt$313.95M
Book value / share$-6.22
Shares outstanding37.18M
Float11.90M
Short % of float7.94%
Dividend yield—
Beta (5Y)1.33
Valuation & profitability ratios
Trailing P/E—
Forward P/E-3.25
PEG ratio—
Price / sales—
Price / book—
EV / revenue86.53
EV / EBITDA-14.34
Gross margin-217.36%
Operating margin-410.84%
Profit margin0.00%
Return on equity—
Return on assets-25.83%
Debt / equity—
Current ratio0.11
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $23.72M | $34.43M | $33.77M | $35.02M | -31.1% |
| Selling, general & admin | $12.41M | $13.18M | $11.65M | $7.44M | -5.9% |
| Total operating expense | $31.22M | $42.44M | $40.89M | $36.95M | -26.4% |
| Operating income | -$31.22M | -$42.44M | -$40.89M | -$36.95M | +26.4% |
| Net interest income | -$16.20M | -$10.04M | -$2.45M | $29.00K | -61.3% |
| Pre-tax income | -$173.80M | -$18.92M | -$69.05M | -$36.92M | -818.8% |
| Net income | -$173.80M | -$18.92M | -$69.05M | -$36.92M | -818.8% |
| Net income to common | -$173.80M | -$18.92M | -$69.05M | -$36.92M | -818.8% |
| Basic EPS | -4.80 | -0.52 | -1.91 | -1.08 | -823.1% |
| Diluted EPS | -4.80 | -0.89 | -1.91 | -1.08 | -439.3% |
| EBIT | -$157.21M | -$8.17M | -$66.42M | -$36.92M | -1,823.3% |
| EBITDA | -$155.68M | -$6.85M | -$65.45M | -$36.02M | -2,173.0% |
| Basic shares | 36.24M | 36.16M | 36.08M | 34.29M | +0.2% |
| Diluted shares | 36.24M | 59.06M | 36.08M | 34.29M | -38.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $8.69M | $9.29M | $13.52M | $14.85M | -6.5% |
| Cash & short-term investments | $8.69M | $9.29M | $13.52M | $14.85M | -6.5% |
| Total current assets | $10.67M | $11.31M | $19.15M | $27.05M | -5.7% |
| Property, plant & equipment | $46.10M | $54.93M | $57.28M | $46.65M | -16.1% |
| Goodwill & intangibles | $13.75M | $13.75M | $13.75M | $13.75M | 0.0% |
| Total assets | $76.88M | $86.44M | $98.36M | $95.83M | -11.1% |
| Total current liabilities | $8.95M | $48.25M | $16.46M | $24.87M | -81.5% |
| Current debt | — | $38.95M | — | — | — |
| Long-term debt | $256.92M | $55.44M | $82.31M | — | +363.5% |
| Total debt | $288.02M | $126.52M | $120.37M | $48.81M | +127.7% |
| Total liabilities | $295.48M | $134.46M | $130.43M | $59.75M | +119.8% |
| Retained earnings | -$501.53M | -$327.74M | -$308.82M | -$239.77M | -53.0% |
| Shareholder equity | -$218.60M | -$48.02M | -$32.06M | $36.08M | -355.2% |
| Working capital | $1.72M | -$36.94M | $2.69M | $2.17M | +104.7% |
| Net tangible assets | -$232.34M | -$61.77M | -$45.81M | $22.33M | -276.2% |
| Shares issued | 36.43M | 36.18M | 36.12M | 36.14M | +0.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$173.80M | -$18.92M | -$69.05M | -$36.92M | -818.8% |
| Depreciation & amortisation | $1.53M | $1.32M | $972.00K | $892.00K | +15.5% |
| Stock-based compensation | $2.61M | $2.89M | $938.00K | $3.10M | -9.8% |
| Change in working capital | -$1.41M | -$2.10M | -$9.65M | $439.00K | +32.7% |
| Operating cash flow | -$25.76M | -$37.55M | -$47.42M | -$32.48M | +31.4% |
| Capital expenditure | -$542.00K | -$1.88M | -$8.14M | -$2.21M | +71.2% |
| Investing cash flow | -$542.00K | -$1.88M | -$8.13M | -$2.21M | +71.2% |
| Financing cash flow | $25.61M | $34.96M | $53.99M | $44.02M | -26.7% |
| Free cash flow | -$26.30M | -$39.43M | -$55.57M | -$34.69M | +33.3% |
| End cash position | $14.08M | $14.77M | $19.24M | $20.81M | -4.7% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $6.11M | $6.07M | $5.82M | $6.39M | $5.43M | — | +0.7% |
| Selling, general & admin | $3.46M | $3.43M | $3.11M | $2.62M | $3.25M | — | +1.1% |
| Total operating expense | $8.79M | $8.41M | $7.78M | $6.84M | $8.19M | — | +4.4% |
| Operating income | -$8.79M | -$8.41M | -$7.78M | -$6.84M | -$8.19M | — | -4.4% |
| Net interest income | -$5.50M | -$4.70M | -$4.26M | -$3.70M | -$3.54M | — | -16.9% |
| Pre-tax income | -$115.35M | -$124.30M | -$26.68M | -$16.30M | -$6.53M | — | +7.2% |
| Net income | -$115.35M | -$124.30M | -$26.68M | -$16.30M | -$6.53M | — | +7.2% |
| Net income to common | -$115.35M | -$124.30M | -$26.68M | -$16.30M | -$6.53M | — | +7.2% |
| Basic EPS | -3.16 | — | -0.74 | -0.45 | -0.18 | 0.07 | — |
| Diluted EPS | -3.16 | — | -0.74 | -0.45 | -0.20 | -0.23 | — |
| EBIT | -$109.79M | -$119.46M | -$22.33M | -$12.49M | -$2.93M | — | +8.1% |
| EBITDA | -$109.33M | -$119.05M | -$21.96M | -$12.12M | -$2.55M | — | +8.2% |
| Basic shares | 36.53M | — | 36.23M | 36.19M | 36.18M | 36.18M | — |
| Diluted shares | 36.53M | — | 36.23M | 36.19M | 59.48M | 36.18M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $4.75M | $8.69M | $14.76M | $4.33M | $11.69M | — | -45.3% |
| Cash & short-term investments | $4.75M | $8.69M | $14.76M | $4.33M | $11.69M | — | -45.3% |
| Total current assets | $5.95M | $10.67M | $16.93M | $7.52M | $13.17M | — | -44.3% |
| Property, plant & equipment | $45.17M | $46.10M | $52.48M | $53.16M | $53.97M | — | -2.0% |
| Goodwill & intangibles | $13.75M | $13.75M | $13.75M | $13.75M | $13.75M | — | 0.0% |
| Total assets | $69.80M | $76.88M | $89.52M | $80.79M | $87.25M | — | -9.2% |
| Total current liabilities | $9.23M | $8.95M | $139.95M | $120.08M | $110.54M | — | +3.1% |
| Current debt | — | — | $131.08M | $112.34M | $102.78M | $38.95M | — |
| Long-term debt | $342.90M | $256.92M | $15.24M | — | — | $55.44M | +33.5% |
| Total debt | $373.67M | $288.02M | $177.68M | $143.96M | $134.66M | — | +29.7% |
| Total liabilities | $381.39M | $295.48M | $185.10M | $150.29M | $141.03M | — | +29.1% |
| Retained earnings | -$616.88M | -$501.53M | -$377.24M | -$350.56M | -$334.27M | — | -23.0% |
| Shareholder equity | -$311.59M | -$218.60M | -$95.59M | -$69.50M | -$53.78M | — | -42.5% |
| Working capital | -$3.28M | $1.72M | -$123.02M | -$112.56M | -$97.37M | — | -290.7% |
| Net tangible assets | -$325.33M | -$232.34M | -$109.33M | -$83.25M | -$67.53M | — | -40.0% |
| Shares issued | 36.64M | 36.43M | 36.23M | 36.19M | 36.19M | — | +0.6% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$115.35M | -$124.30M | -$26.68M | -$16.30M | -$6.53M | +7.2% |
| Depreciation & amortisation | $457.00K | $418.00K | $370.00K | $366.00K | $377.00K | +9.3% |
| Stock-based compensation | $1.07M | $632.00K | $622.00K | $575.00K | $781.00K | +70.1% |
| Change in working capital | $899.00K | -$33.00K | $1.81M | -$2.00M | -$1.20M | +2,824.2% |
| Operating cash flow | -$5.78M | -$6.67M | -$4.30M | -$7.21M | -$7.58M | +13.4% |
| Capital expenditure | -$63.00K | -$52.00K | -$242.00K | -$149.00K | -$99.00K | -21.2% |
| Investing cash flow | -$63.00K | -$52.00K | -$242.00K | -$149.00K | -$99.00K | -21.2% |
| Financing cash flow | $641.00K | $658.00K | $14.97M | $0 | $9.99M | -2.6% |
| Free cash flow | -$5.84M | -$6.73M | -$4.54M | -$7.36M | -$7.68M | +13.1% |
| End cash position | $8.87M | $14.08M | $20.15M | $9.72M | $17.08M | -37.0% |
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
2.50
-51.0% from spot
ATM implied vol
123.4%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
8
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
5.00
9 contracts
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.45 | 1.20 | +368.5% |
| Mar 2026 | -0.38 | -3.16 | -731.6% |
| Dec 2025 | -0.19 | -0.36 | -89.9% |
| Sep 2025 | -0.42 | -0.33 | +20.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.57 | 1 | $900.00K | -22.4% |
| Next quarter | -0.57 | 1 | $1.03M | -5.1% |
| Current year | -2.27 | 1 | $5.20M | +6.0% |
| Next year | -1.40 | 2 | $2.75M | -47.1% |
Analyst targets & ownership
Mean target$17.50
High target$20.00
Low target$15.00
Implied upside243.14%
Analyst count2
ConsensusSTRONG BUY
Strong buy / Buy0 / 2
Hold0
Sell / Strong sell0 / 0
Held by insiders67.64%
Held by institutions13.45%
Institutions holding75
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.62
+10.46% from price
SMA 20
4.69
+8.77% from price
SMA 50
5.34
-4.47% from price
SMA 100
7.55
-32.43% from price
SMA 200
7.55
-32.41% from price
EMA 12
4.71
+8.37% from price
EMA 26
4.86
+4.95% from price
EMA 50
5.49
-7.07% from price
RSI (14)
52.7
Neutral
MACD (12,26,9)
-0.15
Hist 0.10
ATR (14)
0.53
10.45% of price
Realised vol 30D
123.6%
Annualised
Bollinger upper
5.18
20, 2σ
Bollinger lower
4.20
20, 2σ
50 / 200 cross
Death
5.34 vs 7.55
Trend bias
Below 200
-32.41%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.23
Less volatile than market
Correlation to SPY
0.02
Largely independent
Realised vol 30D
123.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-74.6%
Peak to trough
Max drawdown 5Y
-85.8%
Peak to trough
ATR 14
0.53
10.45% of price
Beta (reported)
1.33
5Y monthly, from filing
Short interest
Shares short
856.36K
Prior 441.16K
Change vs prior
+94.1%
Shorts adding
% of float
7.94%
Normal
% of shares out
2.33%
Against total outstanding
Days to cover
5.4
Crowded exit
Float
11.90M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 23, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 5, 26 | Jones Trading | INITIATED | — | Buy |
| May 19, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 19, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 14, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 12, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 15, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 11, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 8, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 22, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 14, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 12, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateMay 10, 2019
Last split1:14
Split dateMay 10, 2019
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-07-20
Corporate Changes & Voting Matters
8-K · 2026-07-13
Corporate Changes & Voting Matters
8-K/A · 2026-06-24
Corporate Changes & Voting Matters
8-K · 2026-06-23
Corporate Changes & Voting Matters
8-K · 2026-06-16
Periodic Financial Reports
10-Q · 2026-05-13
Corporate Changes & Voting Matters
8-K · 2026-05-07
Headlines
Bronchiectasis Market is Expected to Surge at a CAGR of 15% by 2036, Owing to the Launch of DPP1/CatC Inhibitors, Therapeutic Phage Cocktails, Nebulized Mucoactive Agents, and Other Novel Mechanisms | DelveInsight
PR Newswire · 10d ago
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
PR Newswire · 11d ago
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?
Zacks · 33d ago
Armata Pharmaceuticals Names David House as CFO; Advances Staphylococcus Aureus Treatment Candidate
MT Newswires · 34d ago
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
PR Newswire · 34d ago
Armata Pharma Reaches FDA Agreement on Pediatric Study Plan for AP-SA02
MT Newswires · 41d ago
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
PR Newswire · 41d ago
Sector Update: Healthcare Stocks Mixed Pre-Bell Tuesday
MT Newswires · 61d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.